Spyre Therapeutics, Inc. — Director's Dealing 2021

Jul 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2021-07-06

Reporting Person: Alspaugh Jonathan (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-06	Employee Stock Option (right to buy)	$7.03	A	160000	Acquired	2031-07-05	Common Stock (160000)	Direct

Footnotes

F1: The options will vest as to 1/4th of the total shares on July 6, 2022, and then 1/48th of the shares will vest monthly thereafter, such that the option is fully vested on July 6, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.